Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 75, Issue 18, Pages 2352-2371Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2020.03.031
Keywords
cardiovascular therapy; coronavirus; health system
Categories
Funding
- National Institutes of Health/National Heart, Lung, and Blood Institute [T32 HL007854]
- ALung Technologies
- Medtronic
- Boston Scientific
- Abbott Vascular
- Abiomed
- CSI
- Philips
- ReCor Medical
- Yale
- U.S. Food and Drug Administration
- Johnson & Johnson, through Yale University
- Shockwave Medical
- TriReme Medical
- Sumodics
- Silk Road Medical
- National Institutes of Health
Ask authors/readers for more resources
The coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 that has significant implications for the cardiovascular care of patients. First, those with COVID-19 and pre-existing cardiovascular disease have an increased risk of severe disease and death. Second, infection has been associated with multiple direct and indirect cardiovascular complications including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism. Third, therapies under investigation for COVID-19 may have cardiovascular side effects. Fourth, the response to COVID-19 can compromise the rapid triage of non-COVID-19 patients with cardiovascular conditions. Finally, the provision of cardiovascular care may place health care workers in a position of vulnerability as they become hosts or vectors of virus transmission. We hereby review the peer-reviewed and pre-print reports pertaining to cardiovascular considerations related to COVID-19 and highlight gaps in knowledge that require further study pertinent to patients, health care workers, and health systems. (C) 2020 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available